Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF-Reference-Cited by-同舟云学术

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF

Published:2011-07-04 Issue:4 Volume:31 Page:446-457
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Xing F,Persaud Y,Pratilas C A,Taylor B S,Janakiraman M,She Q-B,Gallardo H,Liu C,Merghoub T,Hefter B,Dolgalev I,Viale A,Heguy A,De Stanchina E,Cobrinik D,Bollag G,Wolchok J,Houghton A,Solit D B

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2011250.pdf

Reference43 articles.

1. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR et al. (2008). Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26: 2139–2146.

2. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596–599.

3. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC et al. (1992). Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 89: 4549–4553.

4. Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O et al. (2010). Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 17: 376–387.

5. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr WE et al. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41: 544–552.

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tartrolon D induces immunogenic cell death in melanoma;Chemico-Biological Interactions;2024-09

2. Scalable and universal prediction of cellular phenotypes;2024-08-12

3. Molecular Dynamics Simulation on the Suppression Mechanism of Phosphorylation to Ser222 by Allosteric Inhibitors Targeting MEK1/2 Kinase;ACS Omega;2024-07-10

4. Alantolactone enhances the sensitivity of melanoma to MAPK pathway inhibitors by targeting inhibition of STAT3 activation and down-regulating stem cell markers;Cancer Cell International;2024-05-31

5. Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition;Frontiers in Oncology;2024-05-16